Boehringer Ingelheim launches new trivalent poultry vaccine, includes protection against H5 avian influenza
February 24, 2025 04:30 ET
|
Boehringer Ingelheim Limited
VAXXITEK® HVT+IBD+H5 is a new trivalent vaccine for poultry that offers protection against Marek’s disease, Infectious Bursal Disease and H5 avian influenza in just one shot. H5 avian influenza...
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
February 20, 2025 08:00 ET
|
Boehringer Ingelheim Limited
Ingelheim, Germany, 20 February 2025 – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI...
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
February 19, 2025 07:05 ET
|
Boehringer Ingelheim Limited
Ridgefield, Conn., U.S., and Ingelheim, Germany Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small...
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
February 10, 2025 08:05 ET
|
Boehringer Ingelheim Limited
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52...
Boehringer provides update on iclepertin Phase III program in schizophrenia
January 16, 2025 10:05 ET
|
Boehringer Ingelheim Limited
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were...
Boehringer’s focus on Health Equity drives significant upgrade in Access to Medicine Index Ranking
November 19, 2024 08:15 ET
|
Boehringer Ingelheim Limited
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has been lifted to 8th place in the 2024 Access to Medicine Index (ATMI), up from 13th in 2022. This improvement reflects the...
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
November 12, 2024 05:10 ET
|
Boehringer Ingelheim Limited
·More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing...
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
October 15, 2024 05:30 ET
|
Boehringer Ingelheim Limited
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare...
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
October 08, 2024 02:35 ET
|
Boehringer Ingelheim
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on...
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
September 27, 2024 06:05 ET
|
Boehringer Ingelheim
Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable...